BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Xue J, Ni H, Wang F, Xu K, Niu M. Advances in locoregional therapy for hepatocellular carcinoma combined with immunotherapy and targeted therapy. J Interv Med 2021;4:105-13. [PMID: 34805958 DOI: 10.1016/j.jimed.2021.05.002] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Hui F, Xu C, Xu X, Chen J, Geng H, Yang C, Zhang Y. What Is the Most Suitable Agent Combined With Apatinib for Transarterial Chemoembolization Treatment in Advanced Hepatocellular Carcinoma Patients? A Systematic Review and Network Meta-analysis. Front Oncol 2022;12:887332. [PMID: 35692745 DOI: 10.3389/fonc.2022.887332] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
2 Shen L, Wu Y, Qi H, Jiang Y, Jin J, Cao F, Chen S, Yang Y, Huang T, Song Z, Chen Q, Zhang Y, Mo J, Li D, Zhang X, Fan W. Inducible Regulatory T Cell Predicts Efficacy of PD‐1 Blockade Therapy in Melanoma. Advanced Therapeutics. [DOI: 10.1002/adtp.202100098] [Reference Citation Analysis]
3 Micali C, Russotto Y, Caci G, Ceccarelli M, Marino A, Celesia BM, Pellicanò GF, Nunnari G, Venanzi Rullo E. Loco-Regional Treatments for Hepatocellular Carcinoma in People Living with HIV. Infectious Disease Reports 2022;14:43-55. [DOI: 10.3390/idr14010006] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]